National Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (107)

2024

  1. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

    Cancer Epidemiology, Vol. 92

  2. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    The Journal of clinical investigation, Vol. 134, Núm. 3

  3. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  3. Evaluation of trefoil factor 3 as a non-invasive biomarker of gastric intestinal metaplasia and gastric cancer in a high-risk population

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 411-418

  4. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Clinical Cancer Research, Vol. 29, Núm. 12, pp. 2250-2265

  5. Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide

    The Lancet Oncology, Vol. 24, Núm. 12, pp. e472-e518

  6. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

  7. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  2. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

  3. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer

    Advanced Science, Vol. 9, Núm. 26

2021

  1. Considerations for treatment duration in responders to immune checkpoint inhibitors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  2. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

  3. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma

    JAMA Oncology, Vol. 6, Núm. 5, pp. 724-734

  3. Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma

    PLoS ONE, Vol. 15, Núm. 9 September